pad4 — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T79276	PAD4-IN-2
	PAD4-IN-2 (compound 5i) is a PAD4 inhibitor with an IC50 value of 1.94 μM, shown to suppress tumor growth in mice through specific inhibition of the PAD4-H3cit-NETs pathway in neutrophils [1].
T8861	GSK199		PAD
	GSK199 is a selective PAD4 inhibitor(IC50 of 200 nM in the absence of calcium).		PAD
TQ0067	GSK484 hydrochloride	GTPL8577,AOB6992	PAD
	GSK484 hydrochloride (GTPL8577) (GTPL8577) is a specifc and reversible peptidyl arginine deiminase 4 (PAD4) inhibitor. It demonstrates high-affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium.		PAD
T24105	GSK121	GSK-121,GSK 121	PAD
	GSK121 is an inhibitor of selective PAD4.		PAD
T22277L	BMS-P5 free base		PAD
	BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-...		PAD
T10831L	Cl-amidine hydrochloride		Apoptosis , PAD
	Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor (IC50: 5.9 μM for PAD4). Cl-amidine hydrochloride induces apoptosis in cancer cells and it also induces microRNA (miR)-16 in vitro ca...		Apoptosis , PAD
T22277	BMS-P5		PAD
	BMS-P5 is a specific and orally active Peptidylarginine Deiminase 4 (PAD4) inhibitor.		PAD
T10831	Cl-amidine		Others
	Cl-amidine is an orally active inhibitor of peptidyl arginine deminase (PAD) (IC50s: 0.8 μM, 6.2 μM, and 5.9 μM for PAD1, PAD3, and PAD4). Cl-amidine induces apoptosis in cancer cells.		Others
T10831L2	Cl-amidine TFA		Others
	Cl-amidine TFA is an orally active inhibitor of peptidyl arginine deminase (PAD) (IC50s: 0.8 μM, 6.2 μM, and 5.9 μM for PAD1, PAD3, and PAD4). Cl-amidine induces apoptosis in cancer cells.		Others
T24104	GSK106	GSK-106,GSK 106
	GSK106 is a negative control used in binding and functional assays for PAD4 inhibitors.
T24054	F-amidine
	F-amidine is a bioavailable irreversible PAD4 inactivator.
T36107	YW3-56	YW3-56
	YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor, with an IC50 of 1-5 μM for PAD4. Compared with Cl-amidine, YW3-56 shows >60-fold increase in cell growth inhibition efficacy (IC50 about 2.5 μM) but only 5-f...
T36067	Bongkrekic acid	Bongkrek Acid	ERK , P2X Receptor , p38 MAPK , PAD
	Bongkrekic acid (Bongkrekic Acid (ammonium salt)) is a mitochondrial toxin secreted by Burkholderia gladioli that inhibits adenine nucleotide translocase (ANT).Bongkrekic acid Bongkrekic acid Bongkrekic acid induces extr...		ERK , P2X Receptor , p38 MAPK , PAD
T63601	PAD2-IN-1 hydrochloride
	PAD2-IN-1 hydrochloride is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor with superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold), and is a benzimidazole-based derivative.
T79050	JBI-589
	JBI-589 is an isoform-selective, non-covalent inhibitor of PAD4 that diminishes CXCR2 expression and impedes neutrophil chemotaxis. Additionally, it attenuates primary tumor growth and metastases, augmenting the efficacy...
T39515	PAD2-IN-1	PAD2-IN-1
	PAD2-IN-1, a benzimidazole-based derivative, is an efficacious and specific inhibitor of protein arginine deiminase 2 (PAD2). Demonstrating remarkable selectivity, PAD2-IN-1 exhibits a 95-fold higher affinity for PAD2 in...
T63284	PAD-IN-2
	PAD-IN-2 is a potent inhibitor of pad4 with an IC50 value <1 μM and can be used to study autoimmune diseases and cancers such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, cutaneous lupus erythematos...
T36108	YW3-56 (hydrochloride) (technical grade)	YW3-56 (hydrochloride) (technical grade)
	YW3-56 is an inhibitor of protein arginine deiminase 2 (PAD2) and PAD4 (IC50s = 0.5-1 and 1-5 μM, respectively).1It inhibits the growth of U2OS osteosarcoma cells (IC50= ~2.5 μM) in a p53-dependent mannerviainduction of ...
T36104	Citrulline-specific Probe-Rhodamine
	Protein arginine deiminases (PADs) catalyze the posttranslational modification of arginine residues on proteins to form citrulline, which plays a large role in regulating gene expression. Abnormally high PAD activity has...

Compounds

PAD4-IN-2

T79276

Synonym: GTPL8577,AOB6992

Target: PAD

GSK121

T24105

Synonym: GSK-121,GSK 121

Cl-amidine hydrochloride

T10831L

Synonym:

Target: Apoptosis, PAD

Synonym: GSK-106,GSK 106

Synonym: Bongkrek Acid

Target: ERK, P2X Receptor, p38 MAPK, PAD

PAD2-IN-1 hydrochloride

YW3-56 (hydrochloride) (technical grade)

T36108

Synonym: YW3-56 (hydrochloride) (technical grade)

Target:

Citrulline-specific Probe-Rhodamine

T36104

Synonym:

Target:

Cat No.	Product Name	Synonyms	Targets
T16946	Streptonigrin	Bruneomycin	Others
	Streptonigrin is a natural product produced by Streptomyces flocculus, has both anti-tumor and anti-bacterial activity. Streptonigrin acts as a pan-PAD inhibitor (IC50s: 48.3±34.2 µM, 26.1±0.3 µM, 0.43±0.03 µM, and 2.5±0...

Recombinant Proteins

Species：

Expression System：

Tag：

Cat No.	Product Name	Species	Expression System
TMPY-00021	PADI4 Protein, Human, Recombinant (His)	Human	Baculovirus Insect Cells
	Protein-arginine deiminase type-4, also known as HL-6 PAD, Peptidylarginine deiminase IV, Protein-arginine deiminase type I V and PADI4, is a cytoplasm and nucleus protein that belongs to the protein arginine deiminase f...
TMPK-00501	PADI4 Protein, Cynomolgus, Recombinant (His)	Cynomolgus	E. coli
	Peptidylarginine deiminase type4 (PADI4) was firstly identified as a non-MHC RA genetic risk factor. Furthermore, PADI4 risk allele possessed the association with bone damage regardless of anti citrullinated peptide anti...
TMPK-00502	PADI4 Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated	Cynomolgus	E. coli
	Peptidylarginine deiminase type4 (PADI4) was firstly identified as a non-MHC RA genetic risk factor. Furthermore, PADI4 risk allele possessed the association with bone damage regardless of anti citrullinated peptide anti...
TMPK-01238	PADI4 Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated	Human	E. coli
	Peptidylarginine deiminase type4 (PADI4) was firstly identified as a non-MHC RA genetic risk factor. Furthermore, PADI4 risk allele possessed the association with bone damage regardless of anti citrullinated peptide anti...